Importance of protein flexibility in molecular recognition: a case study on Type-I1/2 inhibitors of ALK?
Physical Chemistry Chemical Physics Pub Date: 2018-01-16 DOI: 10.1039/C7CP08241J
Abstract
Anaplastic lymphoma kinase (ALK) has been regarded as a promising target for the therapy of various cancers. A large number of ALK inhibitors with diverse scaffolds have been discovered, and most of them belong to Type-I inhibitors that only occupy the ATP-binding pocket. Recently, we reported a series of novel and potent Type-I1/2 inhibitors of ALK with the 1-purine-3-piperidinecarboxamide scaffold, which can bind to both the ATP-binding site of ALK and the adjacent hydrophobic allosteric pocket. In this study, the binding mechanisms of these Type-I1/2 ALK inhibitors were elucidated by multiple molecular modeling techniques. The calculation results demonstrate that the ensemble docking based on multiple protein structures and the MM/PB(GB)SA calculations based on molecular dynamics (MD) simulations yield better predictions than conventional rigid receptor docking (Glide, Surflex-Dock, and Autodock Vina), highlighting the importance of incorporating receptor flexibility in the predictions of binding poses and binding affinities of Type-I1/2 ALK inhibitors. Furthermore, the umbrella sampling (US) simulations and MM/GBSA binding free energy decomposition analyses indicate that Leu1122, Leu1198, Gly1202 and Glu1210 in the hinge region and Glu1197, Ile1171, Phe1174, Ile1179, His1247, Ile1268, Asp1270 and Phe1271 in the allosteric pocket of ALK are the key residues for determining the relative binding strength of the studied inhibitors. Besides, we found that the most potent inhibitor (001-017) tends to form stronger transient interactions with residues along the dissociation channel due to the high electronegativity of its bulky 4-(trifluoromethoxy) phenylamine tail. As a whole, both the stronger binding affinity and the higher energetic barrier (which may prolong the drug-target residence time) of 001-017 contribute to its excellent anti-proliferation activity against ALK-positive cancer cells.
Recommended Literature
- [1] An Assessment of the Laminar Hypersonic Double-Cone Experiments in the LENS-XX Tunnel JaideepRay,PatrickBlonigan,EricT.Phipps,KathrynMaupin 10.2514/1.j062802
- [2] An algal process treatment combined with the Fenton reaction for high concentrations of amoxicillin and cefradine Haitao Li,Yu Pan,Zhizhi Wang,Shan Chen,Ruixin Guo,Jianqiu ChenRSC Adv., 2015,5, 100775-100782 10.1039/C5RA21508K
- [3] Aluminium complexes with thio-phosphorus ligands: syntheses and characterisations of [Al2(CyPS3)2(CyPHS2)2] and [Al(S2PPh2)3]? Robert P. Davies,Maria A. Giménez,Laura Patel,Andrew J. P. WhiteDalton Trans., 2008, 5705-5707 10.1039/B813427H
- [4] Alumina grafted SBA-15 sustainable bifunctional catalysts for direct cross-coupling of benzylic alcohols to diarylmethanes? Chandran Rajendran,Govindaswamy Satishkumar,Charlotte Lang,Eric M. GaigneauxCatal. Sci. Technol., 2020,10, 2583-2592 10.1039/D0CY00471E
- [5] An amorphous carbon nitride/NiO/CoN-based composite: a highly efficient nonprecious electrode for supercapacitors and the oxygen evolution reaction? Huifang Yang,Haoran Guo,Peidong Fan,Xinpan Li,Wenlu Ren,Rui SongNanoscale, 2020,12, 7024-7034 10.1039/D0NR00001A
- [6] An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon? Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu MaRSC Adv., 2021,11, 37631-37642 10.1039/D1RA04788D
- [7] Alt-proteins: A promising future 10.1002/fsat.3701_10.x
- [8] An aptasensor for detection of potassium ions based on RecJf exonuclease mediated signal amplification Bidou Wang,Xifeng ChenAnalyst, 2014,139, 5695-5699 10.1039/C4AN01350F
- [9] An aqueous ammonia sensor based on an inkjet-printed polyaniline nanoparticle-modified electrode Karl Crowley,Eimer O'Malley,Aoife Morrin,Malcolm R. Smyth,Anthony J. KillardAnalyst, 2008,133, 391-399 10.1039/B716154A
- [10] An aquatic host–guest complex between a supramolecular G-quadruplex and the anticancer drug doxorubicin? José M. Rivera,Mariana Martín-Hidalgo,Jean C. Rivera-RíosOrg. Biomol. Chem., 2012,10, 7562-7565 10.1039/C2OB25913C
Journal Name:Physical Chemistry Chemical Physics
research_products
-
CAS no.: 89640-58-4